Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 78.4%

Neg 0% Neu 0% Pos 78.4%

Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $13 to $22.